Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA) has granted inducement awards to seven new employees as of April 9, 2025. The awards include stock options for 107,000 shares and restricted stock units (RSUs) covering 83,000 shares, granted under the company's 2021 Inducement Equity Incentive Plan.
The stock options have an exercise price of $2.74 per share, matching the closing price on NASDAQ Global Market on the grant date. These options have a 10-year term and vest quarterly at 1/16th of the shares. The RSUs will fully vest after two years, contingent on continued employment.
Savara Inc. (Nasdaq: SVRA) ha concesso premi di indennità a sette nuovi dipendenti a partire dal 9 aprile 2025. I premi includono opzioni su azioni per 107.000 azioni e unità azionarie vincolate (RSU) che coprono 83.000 azioni, concessi nell'ambito del Piano di Incentivazione Azionaria per Indennità del 2021 della società.
Le opzioni su azioni hanno un prezzo di esercizio di $2,74 per azione, corrispondente al prezzo di chiusura sul NASDAQ Global Market alla data di concessione. Queste opzioni hanno una durata di 10 anni e maturano trimestralmente a 1/16 delle azioni. Le RSU matureranno completamente dopo due anni, a condizione di continuare l'impiego.
Savara Inc. (Nasdaq: SVRA) ha otorgado premios de inducción a siete nuevos empleados a partir del 9 de abril de 2025. Los premios incluyen opciones sobre acciones para 107,000 acciones y unidades de acciones restringidas (RSU) que cubren 83,000 acciones, otorgadas bajo el Plan de Incentivo de Capital por Inducción de 2021 de la empresa.
Las opciones sobre acciones tienen un precio de ejercicio de $2.74 por acción, igualando el precio de cierre en el NASDAQ Global Market en la fecha de concesión. Estas opciones tienen un plazo de 10 años y se adquieren trimestralmente a 1/16 de las acciones. Las RSU se adquirirán completamente después de dos años, sujeto a la continuación del empleo.
사바라 Inc. (Nasdaq: SVRA)는 2025년 4월 9일자로 7명의 새로운 직원에게 유인 보상을 부여했습니다. 보상에는 107,000주에 대한 주식 옵션과 83,000주를 포함하는 제한 주식 단위(RSU)가 포함되어 있으며, 이는 회사의 2021 유인 주식 인센티브 계획에 따라 부여되었습니다.
주식 옵션의 행사가격은 $2.74 per share로, 부여일 NASDAQ 글로벌 마켓의 종가와 일치합니다. 이 옵션은 10년의 기간을 가지며, 주식의 1/16씩 분기별로 매입됩니다. RSU는 2년 후에 완전히 매입되며, 계속 고용되는 조건입니다.
Savara Inc. (Nasdaq: SVRA) a accordé des primes d'incitation à sept nouveaux employés à partir du 9 avril 2025. Les primes comprennent des options d'achat d'actions pour 107 000 actions et des unités d'actions restreintes (RSU) couvrant 83 000 actions, accordées dans le cadre du Plan d'Incitation en Actions de 2021 de la société.
Les options d'achat d'actions ont un prix d'exercice de $2,74 par action, correspondant au prix de clôture sur le NASDAQ Global Market à la date d'attribution. Ces options ont une durée de 10 ans et s'acquièrent trimestriellement à 1/16 des actions. Les RSU seront entièrement acquises après deux ans, sous réserve de la poursuite de l'emploi.
Savara Inc. (Nasdaq: SVRA) hat am 9. April 2025 Anreizprämien an sieben neue Mitarbeiter vergeben. Die Prämien umfassen Aktienoptionen für 107.000 Aktien und eingeschränkte Aktieneinheiten (RSUs), die 83.000 Aktien abdecken, die im Rahmen des Anreiz-Aktienoptionsplans 2021 des Unternehmens gewährt wurden.
Die Aktienoptionen haben einen Ausübungspreis von $2,74 pro Aktie, was dem Schlusskurs am NASDAQ Global Market am Tag der Gewährung entspricht. Diese Optionen haben eine Laufzeit von 10 Jahren und werden vierteljährlich zu 1/16 der Aktien fällig. Die RSUs werden nach zwei Jahren vollständig fällig, vorausgesetzt, dass das Arbeitsverhältnis fortbesteht.
- Employee retention strategy through equity compensation
- Structured vesting schedule promotes long-term commitment
- Potential dilution of existing shareholders due to 190,000 new shares
On April 9, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to seven new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 107,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 83,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company.
The options have an exercise price of
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com, and LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250411807796/en/
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
ir@savarapharma.com
Source: Savara Inc.
FAQ
What is the exercise price of SVRA's new stock options granted on April 9, 2025?
How many shares are covered in Savara's (SVRA) latest inducement awards?
What is the vesting schedule for SVRA's newly granted stock options?
When do the RSUs granted by Savara (SVRA) in April 2025 fully vest?
